Particularly in hepatocellular carcinoma, the Siglec-14/SYK signaling pathway may participate in the progression of hepatocellular carcinoma by modulating inflammatory responses and the immune microenvironment. This evidence concerns the gene SIGLEC14 and hepatocellular carcinoma.